{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:06:00Z","timestamp":1789815960798,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Shandong Provincial Natural Science Foundation","award":["ZR2020MH381"],"award-info":[{"award-number":["ZR2020MH381"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]},{"name":"the Weifang Municipal Science and Technology Bureau","award":["2024GX005, 2021GX062"],"award-info":[{"award-number":["2024GX005, 2021GX062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00228-025-03861-3","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:47:54Z","timestamp":1749512874000},"page":"1129-1139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of PD-1\/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in advanced or metastatic gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7770-031X","authenticated-orcid":false,"given":"Hu","family":"Piao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wenping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chengde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Haoming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Xiaohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yingdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Xuezheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9539","authenticated-orcid":false,"given":"Mao","family":"Shumei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"42","key":"3861_CR1","doi-asserted-by":"publisher","first-page":"e35585","DOI":"10.1097\/MD.0000000000035585","volume":"102","author":"C Liu","year":"2023","unstructured":"Liu C, Tao F, Lu J, Park S, An L (2023) Defining nomograms for predicting prognosis of early and late recurrence in gastric cancer patients after radical gastrectomy. Medicine (Baltimore) 102(42):e35585. https:\/\/doi.org\/10.1097\/MD.0000000000035585","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"3861_CR2","doi-asserted-by":"publisher","first-page":"e38376","DOI":"10.1097\/MD.0000000000038376","volume":"103","author":"C Liu","year":"2024","unstructured":"Liu C, Lu J, An L (2024) Development and validation of nomograms for predicting the prognosis of early and late recurrence of advanced gastric cancer after radical surgery based on post-recurrence survival. Medicine (Baltimore) 103(22):e38376. https:\/\/doi.org\/10.1097\/MD.0000000000038376","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3861_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3748\/wjg.v22.i2.471","volume":"22","author":"O Yazici","year":"2016","unstructured":"Yazici O, Sendur MA, Ozdemir N, Aksoy S (2016) Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 22(2):471\u2013489. https:\/\/doi.org\/10.3748\/wjg.v22.i2.471","journal-title":"World J Gastroenterol"},{"key":"3861_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.critrevonc.2016.02.007","volume":"100","author":"YL Ang","year":"2016","unstructured":"Ang YL, Yong WP, Tan P (2016) Translating gastric cancer genomics into targeted therapies. Crit Rev Oncol Hematol 100:141\u2013146. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.02.007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4730","key":"3861_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1126\/science.2999974","volume":"230","author":"L Coussens","year":"1985","unstructured":"Coussens L, Yang-Feng TL, Liao YC et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730):1132\u20131139. https:\/\/doi.org\/10.1126\/science.2999974","journal-title":"Science"},{"issue":"10","key":"3861_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.4251\/wjgo.v11.i10.804","volume":"11","author":"P Bonelli","year":"2019","unstructured":"Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM (2019) Precision medicine in gastric cancer. World J Gastrointest Oncol 11(10):804\u2013829. https:\/\/doi.org\/10.4251\/wjgo.v11.i10.804","journal-title":"World J Gastrointest Oncol"},{"issue":"11","key":"3861_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497\u20131508. https:\/\/doi.org\/10.1016\/S1470-2045(16)30498-3","journal-title":"Lancet Oncol"},{"issue":"10","key":"3861_CR8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, Wang Z, Fang J et al (2020) Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol 15(10):1636\u20131646. https:\/\/doi.org\/10.1016\/j.jtho.2020.07.014","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3861_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y et al (2021) Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol 16(9):1501\u20131511. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.011","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3861_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y et al (2021) Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med 9(3):305\u2013314. https:\/\/doi.org\/10.1016\/S2213-2600(20)30365-9","journal-title":"Lancet Respir Med"},{"key":"3861_CR11","doi-asserted-by":"publisher","unstructured":"Maoxi Z, Jinmin X, Xiaozhu Z, Yubing Y, Yuxi Z. PD-1\/PD-L1 Inhibitors versus chemotherapy for previously treated advanced gastroesophageal cancer: a meta-analysis of randomized controlled trials.\u00a0J Oncol. 2021;2021:3048974. Published 2021 Sep 16. https:\/\/doi.org\/10.1155\/2021\/3048974","DOI":"10.1155\/2021\/3048974"},{"issue":"7","key":"3861_CR12","doi-asserted-by":"publisher","first-page":"e18332","DOI":"10.1097\/MD.0000000000018332","volume":"99","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Guo Y, Zou CP (2020) Oncological outcomes of addition of anti-PD1\/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: a meta-analysis. Medicine (Baltimore) 99(7):e18332. https:\/\/doi.org\/10.1097\/MD.0000000000018332","journal-title":"Medicine (Baltimore)"},{"key":"3861_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1200\/EDBK_236699","volume":"39","author":"RA De Mello","year":"2019","unstructured":"De Mello RA, Lordick F, Muro K, Janjigian YY (2019) Current and future aspects of immunotherapy for esophageal and gastric malignancies. Am Soc Clin Oncol Educ Book 39:237\u2013247. https:\/\/doi.org\/10.1200\/EDBK_236699","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"21","key":"3861_CR14","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y et al (2023) Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA 330(21):2064\u20132074. https:\/\/doi.org\/10.1001\/jama.2023.19918","journal-title":"JAMA"},{"issue":"10","key":"3861_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6(10):1571\u20131580. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"},{"issue":"2","key":"3861_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS et al (2024) Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 25(2):212\u2013224. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7","journal-title":"Lancet Oncol"},{"key":"3861_CR17","doi-asserted-by":"publisher","unstructured":"Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876. Published 2024 May 28. https:\/\/doi.org\/10.1136\/bmj-2023-078876","DOI":"10.1136\/bmj-2023-078876"},{"key":"3861_CR18","doi-asserted-by":"publisher","unstructured":"B Boku N, Omori T, Shitara K, et al. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer. 2024;27(6):1287\u20131301. https:\/\/doi.org\/10.1007\/s10120-024-01535-0","DOI":"10.1007\/s10120-024-01535-0"},{"key":"3861_CR19","doi-asserted-by":"publisher","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial [published correction appears in Lancet Oncol. 2024 Dec;25(12):e626. https:\/\/doi.org\/10.1016\/S1470-2045(24)00650-8]. Lancet Oncol. 2023;24(11):1181\u20131195. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","DOI":"10.1016\/S1470-2045(24)00650-8"},{"issue":"17","key":"3861_CR20","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M et al (2024) First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol 42(17):2012\u20132020. https:\/\/doi.org\/10.1200\/JCO.23.01601","journal-title":"J Clin Oncol"},{"issue":"19","key":"3861_CR21","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","volume":"32","author":"T Satoh","year":"2014","unstructured":"Satoh T, Xu RH, Chung HC et al (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study. J Clin Oncol 32(19):2039\u20132049. https:\/\/doi.org\/10.1200\/JCO.2013.53.6136","journal-title":"J Clin Oncol"},{"issue":"5","key":"3861_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ejca.2015.01.059","volume":"51","author":"S Lorenzen","year":"2015","unstructured":"Lorenzen S, Riera Knorrenschild J, Haag GM et al (2015) Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer 51(5):569\u2013576. https:\/\/doi.org\/10.1016\/j.ejca.2015.01.059","journal-title":"Eur J Cancer"},{"issue":"5","key":"3861_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht JR, Bang YJ, Qin SK et al (2016) Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2013a randomized phase III trial. J Clin Oncol 34(5):443\u2013451. https:\/\/doi.org\/10.1200\/JCO.2015.62.6598","journal-title":"J Clin Oncol"},{"key":"3861_CR24","doi-asserted-by":"publisher","unstructured":"Wang Y, He K, Zhou Z, Zhong Y, Li G, Lu J. A retrospective study of neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Manag Res. 2020;12:8491\u20138496. Published 2020 Sep 15. https:\/\/doi.org\/10.2147\/CMAR.S267330","DOI":"10.2147\/CMAR.S267330"},{"issue":"5","key":"3861_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","volume":"19","author":"A Cats","year":"2018","unstructured":"Cats A, Jansen EPM, van Grieken NCT et al (2018) Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 19(5):616\u2013628. https:\/\/doi.org\/10.1016\/S1470-2045(18)30132-3","journal-title":"Lancet Oncol"},{"issue":"9","key":"3861_CR26","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24(9):1449\u20131458. https:\/\/doi.org\/10.1038\/s41591-018-0101-z","journal-title":"Nat Med"},{"issue":"26","key":"3861_CR27","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMra1314530","volume":"371","author":"AK Rustgi","year":"2014","unstructured":"Rustgi AK, El-Serag HB (2014) Esophageal carcinoma. N Engl J Med 371(26):2499\u20132509. https:\/\/doi.org\/10.1056\/NEJMra1314530","journal-title":"N Engl J Med"},{"issue":"7517","key":"3861_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202\u2013209. https:\/\/doi.org\/10.1038\/nature13480","journal-title":"Nature"},{"issue":"21","key":"3861_CR29","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel 3rd","year":"2018","unstructured":"Kugel CH 3rd, Douglass SM, Webster MR et al (2018) Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin Cancer Res 24(21):5347\u20135356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1116","journal-title":"Clin Cancer Res"},{"key":"3861_CR30","doi-asserted-by":"publisher","unstructured":"Wu Q, Wang Q, Tang X, et al. Correlation between patients\u2019 age and cancer immunotherapy efficacy. Oncoimmunology. 2019;8(4):e1568810. Published 2019 Feb 3. https:\/\/doi.org\/10.1080\/2162402X.2019.1568810","DOI":"10.1080\/2162402X.2019.1568810"},{"issue":"9","key":"3861_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3861_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16(10):626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 1","key":"3861_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10120-002-0203-6","volume":"5","author":"DM Roder","year":"2002","unstructured":"Roder DM (2002) The epidemiology of gastric cancer. Gastric Cancer 5(Suppl 1):5\u201311. https:\/\/doi.org\/10.1007\/s10120-002-0203-6","journal-title":"Gastric Cancer"},{"key":"3861_CR34","first-page":"i","volume":"143","author":"Cancer incidence in five continents","year":"1997","unstructured":"Cancer incidence in five continents (1997) Volume VII. IARC Sci Publ 143:i\u20131240","journal-title":"IARC Sci Publ"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03861-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03861-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03861-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T06:23:46Z","timestamp":1753079026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03861-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3861"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03861-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}